Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice
- 17 December 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1359-1370
Abstract
Aims: Oral antidiabetic drugs dapagliflozin and chiglitazar have shown potential effects in improving myocardial metabolism. This study aimed to investigate their combined impacts on cardiac energy metabolism in high‐fat diet (HFD)‐induced obesity mice. Methods: Male C57BL/6N mice were randomized into seven groups: (1) normal chow control, (2) high‐fat diet (HFD) control, (3) dapagliflozin monotherapy, (4) low dose of chiglitazar monotherapy, (5) high dose of chiglitazar monotherapy and (6, 7) combination therapy groups with dapagliflozin and varying doses of chiglitazar. Myocardial tissues were subjected to targeted metabolomic analysis for free fatty acids (FFAs) species and key intermediates in central carbon metabolism pathways. Results: The combination therapy significantly improved overall metabolic phenotypes and reduced cardiac lipid droplet size in HFD mice. FFAs profile analysis showed an increased proportion of unsaturated FFAs and a decreased proportion of saturated FFAs. The central carbon metabolism analysis demonstrated alterations in energy metabolic pathways, including glycolysis, purine and pyrimidine metabolism, amino acid metabolism, and the tricarboxylic acid (TCA) cycle. Combined analysis of FFAs and central carbon showed that the TCA cycle was accelerated and ATP production was increased compared with monotherapy. Decreased expression of acetyl‐CoA carboxylase 1, increased expression of carnitine palmitoyltransferase 1, as well as elevated levels of citrate synthase and isocitrate dehydrogenase, were validated by Western blot. Conclusions: The combination of dapagliflozin and chiglitazar improved cardiac fatty acid and central carbon metabolism, among which acceleration of metabolic flux through the TCA cycle, increased ATP production, and upregulation of key enzyme expression might represent the key beneficial mechanisms.Keywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z201100005520011)
- National Key Research and Development Program of China (2018YFC2001100)
- National Natural Science Foundation of China (82170854;82470873)
- Fundamental Research Funds for the Central Universities (3332021094)
This publication has 22 references indexed in Scilit:
- Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidationJournal of Hepatology, 2023
- Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functionsProgress in Lipid Research, 2022
- Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetesMetabolism, 2021
- Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)Science Bulletin, 2021
- Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)Science Bulletin, 2021
- A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)European Journal of Heart Failure, 2019
- A high‐fat diet impairs mitochondrial biogenesis, mitochondrial dynamics, and the respiratory chain complex in rat myocardial tissuesJournal of Cellular Biochemistry, 2018
- Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndromeThe Journal of Nutritional Biochemistry, 2014
- Lipid Metabolism and Toxicity in the HeartCell Metabolism, 2012
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985